Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Trading DecisionHold
Generated at:2026-04-17 17:46:14
Analysis based on technical indicators (moving averages, MACD, RSI, Bollinger Bands, KDJ), fundamental financial data (FY2025 revenue $1.94B, net loss -$2.82B, valuation metrics), pipeline development updates, and market structure data (17.8% short interest). Data time range includes recent price action up to April 17, 2026, with forward-looking catalysts through August 2026.
Summary

Moderna, Inc. (MRNA) represents a high-risk, high-reward investment during a critical transition phase. The analysis recommends HOLD with a target price range of $51.50-$56.00, using the midpoint of $53.75 as the target price. A stop-loss price is set at $51.40 based on the 20-day moving average support level. The confidence level is 0.65, reflecting cautious optimism balanced against fundamental challenges. The risk score is 0.75, indicating high risk due to binary catalysts, financial transition, and extreme volatility.

Operation strategy
  • For existing shareholders: HOLD positions with a cautiously bullish bias
  • For existing shareholders: Consider placing protective stops just below $51.40 (20-day MA) on a closing basis
  • For existing shareholders: Partial profit-taking could be considered on a break above $56.10 with volume confirmation
  • For potential new investors: WAIT for better entry point
  • For potential new investors: Ideal entry would be a pullback to $51.50-$52.00 support zone on lower volume
  • For potential new investors: Aggressive entry only consider on high-volume breakout above $56.06 resistance
  • Time horizon: 3-6 months, aligning with upcoming catalysts (Q1 earnings and August FDA decision)

Core Support

Reasoning summary
  • Technical analysis supports cautious optimism with bullish trend structure (MA alignment) and positive momentum indicators (MACD expanding, RSI at 56.95)
  • Key technical levels: Immediate resistance at $55.14 and $56.06; strong support at $51.40-$51.50 and $49.56
  • Warning signs include KDJ overbought conditions (J-value: 91.92) and high-volume pullback suggesting short-term exhaustion
  • Fundamental analysis reveals transitional challenges with revenue declining 39.93% YoY to $1.94B in FY2025 and net loss of -$2.82B
  • Valuation metrics show P/S-TTM of 10.96 reflecting premium pricing for future pipeline potential rather than current fundamentals
  • Pipeline progress includes positive Phase 3 data for flu and RSV vaccines with FDA expedited review for flu vaccine (decision expected August 2026)
  • Near-term catalyst: Q1 2026 earnings report scheduled for May 1, 2026
  • Market structure shows 17.8% short interest creating potential for short squeezes on positive news
  • Upside potential: Successful flu vaccine approval could drive stock toward $65-$75 range over 12-18 months
  • Downside risk: Disappointing Q1 earnings or pipeline setbacks could see stock retest support at $47-$49